Question explored with the scientific record
Can statins cause dementia
The short version: the evidence does not show that statins cause dementia. It points the other way, but the studies are observational, not randomized trials designed to answer this question.
The evidence you have here is a mix of large observational studies and a few randomized trial analyses. The largest umbrella review, covering 7 meta-analyses with sample sizes up to 9 million people, found statins were associated with a reduced risk of dementia, not an increased one [4]. A 2020 target-trial emulation from the Rotterdam Study found that starting a statin made almost no difference in dementia risk over 10 years (risk difference -0.1%, confidence interval crossing zero), but sustained use showed a possible protective effect [3]. A 2014 Taiwan cohort of elderly patients reported a 22% lower hazard of dementia among statin users, with longer use linked to stronger protection [1]. The 2025 ADVANCE analysis in people with type 2 diabetes found no meaningful association either way [2].
The case reports of memory loss [5] and the early small trials showing some cognitive effects [6] are the main signals in the other direction. But those are anecdotes and short-term lab findings, not population-level evidence of harm. The 2009 Cochrane review, which is the gold standard for this question, concluded there was no significant evidence that statins prevent or cause dementia [7]. That is a neutral finding, not a protective one.
| Study type | What it found | Confidence |
|---|---|---|
| Umbrella review of 7 meta-analyses [4] | Reduced dementia risk (RR 0.62 to 0.85) | Moderate (observational) |
| Target-trial emulation (Rotterdam) [3] | No effect on initiation; possible benefit with sustained use | Low to moderate |
| Taiwan cohort (2014) [1] | 22% lower hazard of dementia | Moderate (observational) |
| ADVANCE (2025) [2] | No meaningful association | Low (observational, non-randomized) |
| Cochrane review (2009) [7] | No evidence of effect either way | High (systematic review of RCTs) |
The key limitation: almost none of this evidence comes from randomized trials designed to test dementia as a primary outcome. The Cochrane review pooled the few RCTs that measured cognition and found nothing. The observational studies cannot fully separate whether statins protect the brain or whether the people who take them are healthier in ways that protect their brains. The case reports of memory loss are real for the individuals who experience them, but they are rare and reversible in the documented cases [5].
My call: the evidence does not support the claim that statins cause dementia. The weight of the data points toward a small protective effect or no effect at all. But the question has never been properly tested in a randomized trial designed for that purpose, so the answer is not as solid as it should be. Confidence: moderate.
Sources used 7
-
Statin use and incident dementia: A nationwide cohort study of Taiwan
This nationwide cohort study in Taiwan found that statin use is associated with a significantly lower risk of incident dementia among elderly patients, with variations based on gender and the potency and duration of statin use.
DOI: 10.1016/j.ijcard.2014.03.018 -
Lipoprotein levels and statin treatment related to dementia and cognitive decline in individuals with type 2 diabetes: an observational analysis from the ADVANCE study
In individuals with type 2 diabetes from the ADVANCE trial, baseline LDL cholesterol was associated with incident dementia/cognitive decline, while statin use did not meaningfully alter dementia/CD risk over ~5 years.
DOI: 10.1186/s12933-025-02894-3 -
Emulating a target trial of statin use and risk of dementia using cohort data
Emulating a target trial in the Rotterdam Study, statin initiation showed little 10-year dementia risk difference, while sustained statin use was associated with reduced risks of dementia and dementia or death, though residual confounding and wide CIs limit interpretation.
DOI: 10.1212/wnl.0000000000010433 -
Systemic medications and dementia risk: a systematic umbrella review
An umbrella review of 68 meta-analyses across 11 systemic drug classes in humans finds moderate-certainty evidence that antihypertensives, statins, SGLT2 inhibitors, and GLP-1 receptor agonists are associated with reduced dementia risk, moderate certainty of increased risk with …
DOI: 10.1038/s41380-025-03129-3 -
Statin‐Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature
This study reviews 60 case reports of statin-associated memory loss and evaluates the conflicting evidence regarding the cognitive effects of statins, suggesting that while some patients may experience memory impairment, the overall literature does not support a causal link betw…
DOI: 10.1592/phco.23.7.871.32720 -
Statins and Cognition: What Can We Learn from Existing Randomized Trials?
Across randomized statin trials, cognition is largely unaffected, with no consistent evidence that statins improve or worsen cognitive function or prevent dementia, though small, short-term studies show isolated effects that are not replicated in larger trials.
DOI: 10.1017/s1092852900019817 -
Statins for the prevention of dementia
This systematic review evaluates the efficacy and safety of statins in preventing dementia in older adults at risk, concluding that there is no significant evidence supporting their use for this purpose.
DOI: 10.1002/14651858.cd003160.pub2